Posts

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

Authors: Ayat Zagzoog, Kawthar A. Mohamed, Hye Ji J. Kim, Eunhyun D. Kim, Connor S. Frank, Tallan Black, Pramodkumar D. Jadhav, Larry A. Holbrook & Robert B. Laprairie Published in Scientific Reports November 2020 Abstract The Cannabis sativa plant contains more than 120 cannabinoids. With the exceptions of ∆9-tetrahydrocannabinol (∆9-THC) and cannabidiol (CBD), comparatively little…

Signaling Through the Type 2 Cannabinoid Receptor Regulates the Severity of Acute and Chronic Graft versus Host Disease

Authors: Cheng Yin Yuan, Vivian Zhou, Garrett Sauber, Todd M Stollenwerk, Richard Komorowski, Alicia López, Rosa Maria Tolon, Julian Romero, Cecilia J Hillard, William R Drobyski Published in Blood  October 2020 Abstract Graft versus host disease (GVHD) pathophysiology is a complex interplay between cells that comprise the adaptive and innate arms of the immune system….

Cannabidiol (CBD) as a Promising Anti-Cancer Drug

Authors: Emily S. Seltzer, Andrea K. Watters, Danny MacKenzie, Jr., Lauren M. Granat and Dong Zhang Published in Cancers  October 2020 Abstract Recently, cannabinoids, such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), have been the subject of intensive research and heavy scrutiny. Cannabinoids encompass a wide array of organic molecules, including those that are physiologically produced…

Activation of Cannabinoid Receptor 2 Prevents Colitis-Associated Colon Cancer through Myeloid Cell De-activation Upstream of IL-22 Production

Authors: William Becker, Haider Rasheed Alrafa,Kiesha Wilson, Kathryn Miranda, Courtney Culpepper, Ioulia Chatzistamou, Guoshuai Cai, Mitzi Nagarkatti, Prakash S. Nagarkatti Published in Iscience August 2020 Abstract Summary Intestinal disequilibrium leads to inflammatory bowel disease (IBD), and chronic inflammation predisposes to oncogenesis. Antigen-presenting dendritic cells (DCs) and macrophages can tip the equilibrium toward tolerance or pathology….

Delegitimizing Cannabis Because of Its Recreational Use is the Real Lie

Sherry Yafai, MD encourages the need for healthcare professionals to shift their perspective on cannabis in her column for Emergency Medicine News. “Delegitimizing medications based simply on their potential for recreational use or abuse is a dangerous and uninformed approach for physicians.”

Understanding Cannabis-Based Therapeutics in Sports Medicine

SCC Member Gretchen E. Maurer, DO, MS and colleagues examine the current research potential for cannabis in sports medicine.

A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men

Authors: Hriday P. Bhambhvani BS, Alex M.Kasman MD, Genester Wilson-King MD, Michael L. Eisenberg MD Published in Sexual Medicine September 2020 Abstract Introduction Cannabis is the most commonly used drug in the United States; however, the effects of cannabis use on male sexual function are poorly understood. Aim To characterize the contemporary landscape of cannabis…

Terpenes/Terpenoids in Cannabis: Are They Important?

Authors: Hanuš LO. · Hod Y. Published in Karger  August 2020 Abstract Cannabis sativa plant has not only cannabinoids as crucial compounds but also the other compounds that play important role as synergistic and/or entourage compound. Cannabis/hemp plant materials and essential oils were analyzed with the help of gas chromatography/mass spectrometry detector for the content of…

Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors

Authors: Belén Palomares, Martín Garrido‐Rodriguez, Claudia Gonzalo‐Consuegra, María Gómez‐Cañas, Suwipa Saen‐oon, Robert Soliva, Juan A. Collado, Javier Fernández‐Ruiz, Gaetano Morello, Marco A. Calzado, Giovanni Appendino, Eduardo Muñoz Published in British Journal of Pharmacology  June 2020 Abstract Background and Purpose: Δ9‐Tetrahydrocannabinolic acid (Δ9‐THCA‐A), the precursor of Δ9‐THC, is a non‐psychotropic phytocannabinoid that shows PPARγ agonist activity. Here,…

Alleviative effects of Cannabis flower on migraine and headache

Author: Sarah S. Stitha, Jegason P.Diviant, Franco Brockelman, KeenanKeeling, BrandenHall, Storri Lucern, Jacob M.Vigil, Kathleen MacMillan MacMillan, Amanda Keddy, James Furlon Published in Science Direct July 2020 Abstract Objective: Few studies to date have measured the real-time effects of consumption of common and commercially available Cannabis products for the treatment of headache and migraine under naturalistic…

Topical Δ9‐Tetrahydrocannabinol and Aqueous Dynamics in Glaucoma

Author: JOHN C. MERRITT M.D. DWIGHT D. PERRY M.D. DAVID N. RUSSELL M.D. BRENDA F. JONES M.D. Published in American College of Clinical Pharmacology  September 1981 Abstract Systemic Δ9‐tetrahydrocannabinol (THC), administered either by smoking marihuana or as synthetic THC in soft gelatin capsules, lowers ocular tension in various glaucomas, but at the expense of significant decreases…

Experiences with Administration of Marihuana to Glaucoma Patients

Author: Robert S. HeplerRobert J. Petrus Published in Springer Link  1976 Abstract In 1971 Hepler and Frank reported reduction in intraocular pressure occurring after healthy young adults smoked marihuana. These initial observations led to additional studies designed to compare the pressure-reducing effects of placebo, smoked marihuana, and injected THC. Consistent, statistically-significant pressure reduction was observed in…